Floatz logo

Surufatinib

Pancreatic Ductal Adenocarcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

279 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
OHSU Knight Cancer Institute
Phase 2BB
Rmc-6236
Tango Therapeutics, Inc.
Phase 3BB
S-1
Genentech, Inc.
Phase 2BB
Xaliplatin
Jonsson Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Surufatinib is also rated in:

neuroendocrine neoplasmActive
BB
Indicative · Phase 3
64 / 100
View asset →
malignant pancreatic neoplasmActive
BB
Indicative · Phase 3
64 / 100
View asset →
colorectal cancerActive
B
Indicative · Phase 2
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →